BI-1831169
- Generic Name
- BI-1831169
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 190
- Registration Number
- NCT05155332
- Locations
- 🇦🇹
Salzburg Cancer Research Institute, Salzburg, Austria
🇪🇸Hospital Quiron. I.C.U., Barcelona, Spain
🇺🇸Banner MD Anderson Cancer Center-Gilbert-55251, Gilbert, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath